Ebola: WHO lists bioMérieux's Biofire test on emergency use list
bioMérieux announced on October 19, 2026 that the World Health Organization (WHO) had granted emergency use listing (EUL) to its Biofire Global Fever Special Pathogens panel, a differential diagnostic test. The decision comes in the context of the Bundibugyo Ebola epidemic affecting the Democratic Republic of Congo (DRC) and neighboring countries, a strain against which no specific treatment or approved vaccine has been developed, according to the company statement.
A test detecting 16 pathogens including Bundibugyo Ebola
Manufactured by BioFire Defense, a bioMérieux group company specializing in detecting biological threats for U.S. government agencies, the panel allows simultaneous screening for 16 pathogens from a single whole blood sample in approximately one hour. Among these are several Ebola viruses, malaria parasites as well as Marburg, West Nile and Lassa viruses. The test notably detects Bundibugyo Ebola virus, the source of the current epidemic, a capability developed several years before its emergence, according to the group. The stated objective is to distinguish Ebola from other causes of acute fever with similar symptoms, in order to accelerate clinical decision-making and better utilize limited health resources. According to the company, EUL listing constitutes an international reference providing health authorities, international organizations and purchasing partners an additional expedited pathway to consider using the panel, both in response to the ongoing epidemic and in preparation for future crises. The test also holds FDA authorization and is recommended by the U.S. Centers for Disease Control and Prevention (CDC) for response to the current epidemic. "WHO emergency use listing is an important step for epidemic preparedness and response," said Charles K. Cooper, Executive Vice President and Chief Medical Officer of bioMérieux.
Deliveries in Rwanda and Uganda, ongoing support in DRC
Since the start of the epidemic, bioMérieux indicates it has been working with health ministries, public health agencies and local partners to assess diagnostic needs and strengthen laboratory capacities. The group specifies that it has increased its production capacity, accelerated delivery of instruments and tests, and ensured training and on-site support for laboratory teams. In June, instruments and reagents were delivered to Rwanda Biomedical Centre, with support for training and implementation. Instruments and reagents were also delivered to Uganda National Health Laboratory Services as part of Uganda's preparedness efforts.
In the DRC, bioMérieux is working with the National Institute of Biomedical Research (INRB) and health authorities to provide additional instruments and tests.
These contributions are presented as complementary to existing diagnostic capacities, for suspected cases requiring further investigation through differential molecular testing. "Our objective is to help health authorities not only respond to the current epidemic, but also strengthen preparedness for future health threats," said Vanina Laurent-Ledru, Director of Public Health and Government Affairs for the group.
